Status:
COMPLETED
Pharmacogenetics Associated With IV Ketamine
Lead Sponsor:
Brain and Cognition Discovery Foundation
Conditions:
Treatment Resistant Depression
Eligibility:
All Genders
18-65 years
Brief Summary
The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from tr...
Eligibility Criteria
Inclusion
- Must have received IV ketamine previously to treat Treatment-Resistant Depression
- Between the ages of 18-65 years old.
- Clinical diagnosis of MDD
- Individuals may have had comorbid psychiatric conditions (e.g., anxiety), but the comorbid psychiatric condition cannot be the primary clinical concern.
- Ability to provide informed consent
Exclusion
- Individuals who meet DSM 5 criteria for a substance use and/or alcohol use disorder in the past 3 months.
- Individuals who are currently experiencing psychotic symptoms as part of an MDE (mood congruent/mood incongruent).
- Individuals who are unable to consent to the procedure.
- Individuals who are unable to adhere to the protocol in its totality
Key Trial Info
Start Date :
January 21 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 2 2021
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT04695405
Start Date
January 21 2021
End Date
July 2 2021
Last Update
August 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Canadian Rapid Treatment Centre of Excellence
Mississauga, Ontario, Canada, L5C 4E7